A Single Center, Randomized, Open-Label, Sequential, Single Dose, 4-Period Crossover Study to Evaluate the Bioavailability and Food Effect of a Gelatin Formulation and Two Prototype Formulations of Afuresertib, an AKT Inhibitor, in Normal Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Afuresertib (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- 10 Jun 2017 Biomarkers information updated
- 05 Jul 2013 Planned End Date changed from 1 Jun 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.